Bodypharm Tesamorelin 10 mg Vial

Body Pharm Tesamorelin 10mg: Benefits, Dosing & Buyer Guide 2026
Body Pharm Tesamorelin 10mg is a lyophilised GHRH-analogue peptide sold in South Africa as a single 10mg vial. A sister format, the Body Pharm Tesamorelin 32 pen, covers longer protocols without reconstitution. The clinical case is concrete: a 2026 meta-analysis of five randomised controlled trials reported a mean visceral adipose tissue reduction of about 27.7 cm² over roughly 26 weeks in HIV-associated lipodystrophy at 2mg/day. This happens because GHRH stimulation drives pulsatile release of endogenous growth hormone, which is both anabolic and lipolytic, raising IGF-1 (insulin-like growth factor 1) and accelerating lipolysis in visceral depots. Outside that indication, use is off-label and unverified.

Tesamorelin is not separately registered with SAHPRA and is treated as a prescription-only peptide accessible in 2026 through Section 21 named-patient authorisation under the Medicines and Related Substances Act (Act 101 of 1965). South African law restricts unregistered growth-hormone-axis medicines to named-patient importation or pharmacy compounding under a prescriber. Beskinny lists the 10mg vial alongside the 32 pen at beskinny.store for live cost-per-mg checks.

Key Takeaways
Tesamorelin reduces visceral fat by roughly 15% over 26 weeks at 2mg/day in HIV-associated lipodystrophy — its only approved indication.
The 2026 meta-analysis pooled five RCTs and reported a mean visceral fat reduction of about 27.7 cm² and a mean hepatic-fat reduction of about 4.3 percentage points.
Off-label use in healthy adults for cosmetic fat loss is unverified and carries metabolic risks (glucose dysregulation, elevated IGF-1).
Two Body Pharm formats are stocked: the 10mg vial (flexible titration, requires mixing) and the 32 pen (full-cycle convenience, pre-filled).
Baseline labs (fasting glucose, HbA1c, IGF-1) and periodic monitoring are essential because tesamorelin can cause glucose intolerance and raises serum IGF-1.
Visceral fat re-accumulates within months of stopping because the growth-hormone stimulus is removed.